ArticleCureus2025
Targeting COX-2 to Alleviate Depressive Phenotypes: Etoricoxib's Antidepressant Effects in Chronic Unpredictable Mild Stress-Exposed Mice.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current study evaluated the antidepressant effect of etoricoxib, a well-established non-steroidal anti-inflammatory drug, in the chronic unpredictable mild stress (CUMS) model of depression in Swiss albino mice. The mice were exposed to CUMS for 42 days by using a variety of stressors. A total of 54 Swiss albino mice of either sex were used for the study, which were tested for locomotor activity using the Open Field Test (OFT). The mice were randomly divided into four groups, each with six animals, which were used to evaluate the antidepressant effect of etoricoxib using the Forced Swim Test (FST). For the prolonged experiment, the remaining 30 mice were used to evaluate the antidepressant effect using the chronic mild stress model (CMS), followed by a sucrose preference test (SPT) for six weeks. Treatment with etoricoxib at any of the doses (3 mg/kg and 9 mg/kg, PO) and the positive control, fluoxetine, significantly reversed these behavioral changes as compared to the CUMS using the OFT. The etoricoxib at 3 mg/kg and 9 mg/kg doses administered to stressed animals produced a significant (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.